We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M Turnover 44.83%
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
-8.7%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$4.8B
AUM Growth
+$87.7M
Cap. Flow
+$390M
Cap. Flow %
8.12%
Top 10 Hldgs %
41.63%
Holding
117
New
20
Increased
33
Reduced
18
Closed
25
Avg Time Held Equity + Options
0.8 years
Top 10 Avg Time Held Equity + Options
0.7 years
Top 20 Avg Time Held Equity + Options
0.6 years
Avg Time Held Equity only
0.8 years
Top 10 Avg Time Held Equity only
0.7 years
Top 20 Avg Time Held Equity only
0.6 years

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$187M
2
ISRG icon
Intuitive Surgical
ISRG
+$94.9M
3
HUM icon
Humana
HUM
+$83.2M
4
BIIB icon
Biogen
BIIB
+$79.4M
5
UNH icon
UnitedHealth
UNH
+$65.8M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$123M
2
ARNA
Arena Pharmaceuticals Inc
ARNA
+$113M
3
LLY icon
Eli Lilly
LLY
+$95.2M
4
HOLX icon
Hologic
HOLX
+$81.5M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$79.1M

Sector Composition

Rank Sector Weight
1 Healthcare 92.34%
2 Miscellaneous 7%
3 Financials 0.49%
4 Technology 0.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
XNTK icon
1
CALL
State Street SPDR NYSE Technology ETF
XNTK
$1.99B
$297M 6.18%
+3,300,000
New +$470M
2022 Q1
0 quarters
AZN icon
2
AstraZeneca
AZN
$259B
$245M 5.11%
1,850,000
+416,400
+29% +$49.9M
2021 Q3
2 quarters
ABBV icon
3
AbbVie
ABBV
$501B
$238M 4.95%
1,466,100
-518,900
-26% -$75.4M
2019 Q4
9 quarters
ARVN icon
4
Arvinas
ARVN
$468M
$196M 4.09%
2,915,300
+387,327
+15% +$26.4M
2020 Q2
7 quarters
ELV icon
5
Elevance Health
ELV
$92.9B
$196M 4.09%
399,400
+78,400
+24% +$35.8M
2021 Q4
1 quarter
MRK icon
6
Merck
MRK
$358B
$194M 4.05%
+2,370,000
New +$187M
2022 Q1
0 quarters
AVTR icon
7
Avantor
AVTR
$10.9B
$192M 3.99%
5,668,300
+876,300
+18% +$31.3M
2020 Q2
7 quarters
BAX icon
8
Baxter International
BAX
$13.3B
$149M 3.09%
1,915,500
+150,500
+9% +$12.6M
2021 Q3
2 quarters
ZNTL icon
9
Zentalis Pharmaceuticals
ZNTL
$212M
$147M 3.05%
3,176,999
+461,999
+17% +$24.9M
2020 Q2
7 quarters
BHVN icon
10
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$146M 3.04%
1,231,000
+91,000
+8% +$11.3M
2020 Q1
8 quarters
VRTX icon
11
Vertex Pharmaceuticals
VRTX
$129B
$142M 2.96%
545,600
+265,600
+95% +$63M
2020 Q4
5 quarters
UNH icon
12
UnitedHealth
UNH
$365B
$132M 2.76%
259,600
+136,500
+111% +$65.8M
2021 Q4
1 quarter
UTHR icon
13
United Therapeutics
UTHR
$23.2B
$129M 2.69%
718,946
+183,946
+34% +$35M
2021 Q2
3 quarters
HZNP
14
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$119M 2.48%
1,131,400
+119,400
+12% +$11.6M
2019 Q4
9 quarters
MRTX
15
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$115M 2.38%
1,393,000
+586,600
+73% +$60M
2020 Q3
6 quarters
ISEE
16
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$109M 2.27%
6,475,400
-479,600
-7% -$7.09M
2021 Q2
3 quarters
NBIX icon
17
Neurocrine Biosciences
NBIX
$13.9B
$109M 2.26%
1,160,000
-100,000
-8% -$8.47M
2020 Q4
5 quarters
IOVA icon
18
Iovance Biotherapeutics
IOVA
$6.67B
$101M 2.1%
6,043,219
+2,263,219
+60% +$35M
2021 Q3
2 quarters
ISRG icon
19
Intuitive Surgical
ISRG
$151B
$98M 2.04%
+325,000
New +$94.9M
2022 Q1
0 quarters
CTLT icon
20
DELISTED
CATALENT, INC.
CTLT
$86.7M 1.81%
782,000
+87,000
+13% +$9.08M
2020 Q3
6 quarters
HUM icon
21
Humana
HUM
$51.9B
$86.6M 1.8%
+198,900
New +$83.2M
2022 Q1
0 quarters
SNDX icon
22
Syndax Pharmaceuticals
SNDX
$1.22B
$83.8M 1.75%
4,823,400
– –
2020 Q2
7 quarters
BIIB icon
23
Biogen
BIIB
$34.8B
$76.9M 1.6%
+365,000
New +$79.4M
2022 Q1
0 quarters
RARE icon
24
Ultragenyx Pharmaceutical
RARE
$1.5B
$63.1M 1.31%
869,000
+169,000
+24% +$11.8M
2021 Q3
2 quarters
JNJ icon
25
Johnson & Johnson
JNJ
$610B
$62.7M 1.31%
+354,000
New +$60.2M
2022 Q1
0 quarters
1
2 3 4 5

Similar funds

ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
CWM
Chemistry Wealth Management New York $625M AUM 19.32% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return
PWS
Proactive Wealth Strategies Marietta, Georgia $623M AUM 30.7% 1-Year Est. Return
LWP
LMG Wealth Partners Shreveport, Louisiana $626M AUM 36.27% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return

Avidity Partners Management's Q1 2022 Portfolio in Review

As of Q1 2022, Avidity Partners Management held 117 positions worth $4.8B, up 1.9% from $4.71B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Avidity Partners Management deployed $390M of net new capital in Q1 2022, opening 20 new positions and adding to 33 existing holdings. Its largest new stake was Merck: 2,370,000 shares worth $194M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Seagen Inc. Common Stock, an estimated $79.1M trimmed.

  • Avidity Partners Management's largest Q1 2022 buy was Merck: 2,370,000 shares worth $194M.
  • Avidity Partners Management added most to UnitedHealth in Q1 2022, an estimated $65.8M increase.
  • Avidity Partners Management's biggest Q1 2022 reduction was Seagen Inc. Common Stock, cutting an estimated $79.1M.
  • Avidity Partners Management fully exited Pfizer in Q1 2022, selling an estimated $123M.
  • Avidity Partners Management's ten largest holdings make up 42% of its $4.8B portfolio in Q1 2022.
  • Avidity Partners Management opened 20 new positions and closed 25 in Q1 2022.
  • Avidity Partners Management's portfolio value rose 1.9% quarter-over-quarter to $4.8B.

Based on Avidity Partners Management's 13F filing for Q1 2022, filed 16 May 2022.